Prostate Cancer Coverage from Every Angle

Maha Hussain, MD, and Eric J. Small, MD, on Prostate Cancer and Antiandrogens: Results From the PROSPER and SPARTAN Trials

Posted: Thursday, June 28, 2018

Maha Hussain, MD, of Northwestern University, and Eric J. Small, MD, of the University of California, San Francisco, discuss two key phase III trials on antiandrogens in nonmetastatic castration-resistant prostate cancer: one explores the use of enzalutamide, and the other looks at apalutamide vs placebo.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.